Other News To Note
Cold Genesys Inc., of Irvine, Calif., reached agreement with the FDA under a special protocol assessment for a proposed Phase II/III pivotal BOND (Bladder Oncolytic virus for Non-muscle invasive bladder cancer Disease) trial of intravesical CG0070 in non-muscle invasive bladder cancer patients with carcinoma-in-situ with Ta and/or T1 who previously failed BCG (Bacillus Calmette-Guerin, a standard intravesical treatment) and refused cystectomy.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter